EMAIL THIS PAGE TO A FRIEND

Journal of neuroimmunology

Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst.


PMID 25175064

Abstract

Neuroinflammation contributes to the pathogenesis of neurological disorders. Anti-inflammatory treatments could potentially be used to slow down the progression of these diseases. We studied the anti-neuroinflammatory activity of gold compounds which have been used to treat rheumatoid arthritis. Non-toxic concentrations of auranofin (0.1-1 μM) significantly reduced the cytotoxic secretions by primary human microglia and microglia-like THP-1 promonocytic cells. Auranofin inhibited primed NADPH-oxidase dependent respiratory burst and secretion of tumor necrosis factor (TNF)-α and nitric oxide by monocytic cells. It had a direct neuroprotective effect on SH-SY5Y neuronal cells. Auranofin could have a novel application in the treatment of neurodegenerative diseases.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

N8285
β-Nicotinamide adenine dinucleotide, pkg of 10 mg (per vial)
C21H27N7O14P2
N8410
β-Nicotinamide adenine dinucleotide, pkg of 20 mg (per vial)
C21H27N7O14P2
N8535
β-Nicotinamide adenine dinucleotide, pkg of 50 mg (per vial)
C21H27N7O14P2
N7004
β-Nicotinamide adenine dinucleotide hydrate, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
C21H27N7O14P2 · xH2O
N6522
β-Nicotinamide adenine dinucleotide hydrate, ≥98%, BioUltra, from yeast
C21H27N7O14P2 · xH2O
N1636
β-Nicotinamide adenine dinucleotide hydrate, purified by column chromatography, ≥99%
C21H27N7O14P2 · xH2O
N3014
β-Nicotinamide adenine dinucleotide hydrate, cell culture tested, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
C21H27N7O14P2 · xH2O
N7381
β-Nicotinamide adenine dinucleotide hydrate, Grade AA-1, ≥95% (HPLC)
C21H27N7O14P2 · xH2O
N1511
β-Nicotinamide adenine dinucleotide hydrate, ≥99%
C21H27N7O14P2 · xH2O
43410
β-Nicotinamide adenine dinucleotide hydrate, ≥95% (HPLC)
C21H27N7O14P2 · xH2O
N7132
β-Nicotinamide adenine dinucleotide lithium salt from Saccharomyces cerevisiae, ≥95%
C21H26LiN7O14P2
A4685
Luminol sodium salt
C8H6N3NaO2
S9251
Sulfanilamide, ≥99%
C6H8N2O2S
46874
Sulfanilamide, VETRANAL, analytical standard
C6H8N2O2S
1632004
Sulfanilamide, United States Pharmacopeia (USP) Reference Standard
C6H8N2O2S
33626
Sulfanilamide, puriss. p.a., ≥99% (calc. to the dried substance)
C6H8N2O2S
S2151000
Sulfanilamide, European Pharmacopoeia (EP) Reference Standard
C6H8N2O2S
PHR1093
Sulfanilamide melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
C6H8N2O2S
1633007
Sulfanilamide Melting Point Standard, United States Pharmacopeia (USP) Reference Standard
C6H8N2O2S